Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + VEX Metronomic Chemotherapy With or Without Radiotherapy in Advanced Triple-negative Breast Cancer
NCT06771609Phase 2
Key facts
- Status
- Recruiting
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- adebrelimab
- Conditions
- triple-negative breast cancer (TNBC)
01
Overview
Phase 2, randomised trial of adebrelimab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 24 months. Started Sep 2024; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Adebrelimab + VEX metronomic chemotherapy + radiotherapy
Adebrelimab 1200mg Q3W + Vinorelbine 20mg QOD + Cyclophosphamide 50mg QD + Capecitabine 500mg TID + Radiotherapy
Adebrelimab + VEX metronomic chemotherapy
Adebrelimab 1200mg Q3W + Vinorelbine 20mg QOD + Cyclophosphamide 50mg QD + Capecitabine 500mg TID
03
Who it enrols
Adults with metastatic triple-negative breast cancer who have received ≤1 line of chemotherapy for metastatic disease, have an ECOG performance status of 0 or 1, and have at least one measurable lesion.
04
Endpoints
Primary
Progression-Free Survival
Beyond the preview
Go deeper on NCT06771609.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771609.